Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1995 Jan;50(1):62–66. doi: 10.1136/thx.50.1.62

Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease.

A Ikeda 1, K Nishimura 1, H Koyama 1, T Izumi 1
PMCID: PMC473711  PMID: 7886652

Abstract

BACKGROUND--Inhaled anticholinergics and beta agonists are widely used in the treatment of patients with chronic obstructive pulmonary disease (COPD). However, dosage requirements have not been thoroughly evaluated and comparative dose-response data for these agents are limited. METHODS--Twenty men with stable COPD of mean (SD) age 69.4 (5.8) years and FEV1 0.93 (0.38) litres were studied in randomised, double blind, crossover, placebo controlled experiments. All of the patients received two, four, eight, and 16 puffs of ipratropium bromide (20 micrograms/puff), flutropium bromide (30 micrograms/puff), oxitropium bromide (100 micrograms/puff), fenoterol (200 micrograms/puff), or placebo in random order on five separate days. Doses were administered by a metered dose inhaler at intervals of 60 minutes to give cumulative doses of two, six, 14, and 30 puffs. Five mg of nebulised salbutamol was administered 60 minutes after the patient had received the final 16 puffs of each regimen. Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), heart rate, and blood pressure were measured five minutes before each treatment and 30 minutes after treatment with nebulised salbutamol. RESULTS--FEV1 and FVC reached a plateau after administration of a cumulative dose of 14 puffs of ipratropium bromide (280 micrograms) or flutropium bromide (420 micrograms), and after six puffs of oxitropium bromide (600 micrograms). There were no differences with respect to maximum increases in FEV1 and FVC amongst the three anticholinergic agents. However, after six puffs oxitropium bromide produced a greater increase in FEV1 than either ipratropium bromide or flutropium bromide. Fenoterol caused a greater increase in both FEV1 and FVC than the three anticholinergic agents after six puffs, as well as a greater increase in pulse rate. Oxitropium bromide produced a greater increase in pulse rate than the other anticholinergics after 14 puffs. The incidence of side effects was dose-related and notable adverse effects were reported after 30 puffs of ipratropium bromide, 14 puffs of oxitropium bromide, and two puffs of fenoterol. CONCLUSIONS--Oxitropium bromide produced a greater bronchodilator effect than either ipratropium bromide or flutropium bromide when used at doses of less than six puffs, without apparent side effects. There were, however, no differences in maximal response between these drugs. Fenoterol may have a greater peak bronchodilator effect than the anticholinergic agents but it causes more adverse effects, even at lower doses. Depending upon the balance between efficacy and side effects, oxitropium bromide may be preferred in the treatment of patients with COPD.

Full text

PDF
62

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baigelman W., Chodosh S. Bronchodilator action of the anticholinergic drug, ipratropium bromide (Sch 1000), as an aerosol in chronic bronchitis and asthma. Chest. 1977 Mar;71(3):324–328. doi: 10.1378/chest.71.3.324. [DOI] [PubMed] [Google Scholar]
  2. Banholzer R., Pook K. H., Stiasni M. Synthesis of the bronchospasmolytic agent flutropium bromide and of some homologous and configuration isomeric compounds. Arzneimittelforschung. 1986 Aug;36(8):1161–1166. [PubMed] [Google Scholar]
  3. Bauer R., Fügner A. Pharmacology of the anticholinergic bronchospasmolytic agent flutropium bromide. Arzneimittelforschung. 1986 Sep;36(9):1348–1352. [PubMed] [Google Scholar]
  4. Braun S. R., McKenzie W. N., Copeland C., Knight L., Ellersieck M. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Arch Intern Med. 1989 Mar;149(3):544–547. [PubMed] [Google Scholar]
  5. Dolovich M. B., Sanchis J., Rossman C., Newhouse M. T. Aerosol penetrance: a sensitive index of peripheral airways obstruction. J Appl Physiol. 1976 Mar;40(3):468–471. doi: 10.1152/jappl.1976.40.3.468. [DOI] [PubMed] [Google Scholar]
  6. Easton P. A., Jadue C., Dhingra S., Anthonisen N. R. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med. 1986 Sep 18;315(12):735–739. doi: 10.1056/NEJM198609183151205. [DOI] [PubMed] [Google Scholar]
  7. Gross N. J., Bankwala Z. Effects of an anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease. Comparison with a beta-adrenergic agent. Am Rev Respir Dis. 1987 Nov;136(5):1091–1094. doi: 10.1164/ajrccm/136.5.1091. [DOI] [PubMed] [Google Scholar]
  8. Hughes J. A., Tobin M. J., Bellamy D., Hutchison D. C. Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema. Thorax. 1982 Sep;37(9):667–670. doi: 10.1136/thx.37.9.667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Koyama H., Nishimura K., Ikeda A., Izumi T. A comparison of the bronchodilating effects of oxitropium bromide and fenoterol in patients with chronic obstructive pulmonary disease. Chest. 1993 Dec;104(6):1743–1747. doi: 10.1378/chest.104.6.1743. [DOI] [PubMed] [Google Scholar]
  10. LeDoux E. J., Morris J. F., Temple W. P., Duncan C. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. Chest. 1989 May;95(5):1013–1016. doi: 10.1378/chest.95.5.1013. [DOI] [PubMed] [Google Scholar]
  11. Lipworth B. J., Clark R. A., Dhillon D. P., McDevitt D. G. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1990 Aug;142(2):338–342. doi: 10.1164/ajrccm/142.2.338. [DOI] [PubMed] [Google Scholar]
  12. Newman S. P., Woodman G., Clarke S. W., Sackner M. A. Effect of InspirEase on the deposition of metered-dose aerosols in the human respiratory tract. Chest. 1986 Apr;89(4):551–556. doi: 10.1378/chest.89.4.551. [DOI] [PubMed] [Google Scholar]
  13. Pavia D., Thomson M. L., Clarke S. W., Shannon H. S. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax. 1977 Apr;32(2):194–197. doi: 10.1136/thx.32.2.194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Peel E. T., Anderson G. A dose response study of oxitropium bromide in chronic bronchitis. Thorax. 1984 Jun;39(6):453–456. doi: 10.1136/thx.39.6.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Peel E. T., Anderson G., Cheong B., Broderick N. A comparison of oxitropium bromide and ipratropium bromide in asthma. Eur J Respir Dis. 1984 Feb;65(2):106–108. [PubMed] [Google Scholar]
  16. Poppius H., Salorinne Y. Comparative trial of a new anticholinergic bronchodilator, Sch 1000, and salbutamol in chronic bronchitis. Br Med J. 1973 Oct 20;4(5885):134–136. doi: 10.1136/bmj.4.5885.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Vathenen A. S., Britton J. R., Ebden P., Cookson J. B., Wharrad H. J., Tattersfield A. E. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis. 1988 Oct;138(4):850–855. doi: 10.1164/ajrccm/138.4.850. [DOI] [PubMed] [Google Scholar]
  18. Wesseling G., Mostert R., Wouters E. F. A comparison of the effects of anticholinergic and beta 2-agonist and combination therapy on respiratory impedance in COPD. Chest. 1992 Jan;101(1):166–173. doi: 10.1378/chest.101.1.166. [DOI] [PubMed] [Google Scholar]
  19. Wong C. S., Pavord I. D., Williams J., Britton J. R., Tattersfield A. E. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet. 1990 Dec 8;336(8728):1396–1399. doi: 10.1016/0140-6736(90)93099-b. [DOI] [PubMed] [Google Scholar]
  20. Yanaura S., Mizuno H., Goto K., Kamei J., Hosokawa T., Ohtani K., Misawa M. Effects of 8-(2-fluoroethyl)-3 alpha-hydroxy-1 alpha H, 5 alpha H-tropaniumbromide benzilate (Ba598Br) on allergy- and drug-induced asthmas. Jpn J Pharmacol. 1983 Oct;33(5):971–982. doi: 10.1254/jjp.33.971. [DOI] [PubMed] [Google Scholar]
  21. van Schayck C. P., Folgering H., Harbers H., Maas K. L., van Weel C. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Thorax. 1991 May;46(5):355–359. doi: 10.1136/thx.46.5.355. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES